Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease

Assistance Publique - Hôpitaux de Paris360 enrolled

Overview

Chronic liver diseases represent a major public health problem and are responsible for more than 150,000 deaths in Europe each year. These diseases are accompanied by symptoms that profoundly alter the quality of life and mainly affect people of working age, leading to a major economic impact. Coagulation disorders, inflammation and vascular alterations are associated with chronic liver diseases but their role in the onset and/or progression of liver diseases is still not fully understood. A better understanding of chronic liver diseases and in particular of the factors that play a role in the onset and progression of these diseases would improve patient management and therefore have a positive impact on individuals, but also on the healthcare system and the economy.

Study Type

OBSERVATIONAL

Enrollment

360

Conditions

Chronic Liver Diseases Coagulation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients with chronic liver disease: Patients over 18 years of age Patients affiliated with a social security plan or entitled to receive benefits Patients with chronic liver disease or cirrhosis whose diagnosis is based on one or more of the following * Liver biopsy showing chronic liver disease or cirrhosis * Liver elastography by Fibroscan® assessing the elasticity of the liver at more than 10 kpa * Combination of clinical, biological and imaging criteria characteristic of chronic liver disease (signs of portal hypertension, liver failure and liver dysmorphia in a patient with at least one risk factor for chronic liver disease) Controls without liver disease Patients 18 years of age with no known liver disease Patients who have had blood drawn in the hospital prior to surgery (pre-operative work-up as part of the care process). Exclusion Criteria: Common non-inclusion criteria for patients with chronic liver disease and controls without liver disease will be as follows: * Pregnant or lactating women * Protected populations: persons under guardianship, under curatorship or safeguard of justice * Patient under AME * Patient who has not signed a consent form * Recent surgery before the blood test (\< 2 weeks) * Transfusion of blood products (packed red blood cells, platelet concentrates, fresh frozen plasma, etc.) recently (\< 2 weeks) * Use of medication that interferes with hemostasis * Active extra-hepatic cancer or cancer less than 5 years old * Organ transplantation (liver, kidney, lung, heart)

Outcomes

Primary Outcomes

Activated partial thromboplastin time abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of activated partial thromboplastin time for each patient at inclusion

Time frame: at 10 years

Factor II abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of factor II for each patient at inclusion

Time frame: at 10 years

Factor V abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of factor V for each patient at inclusion

Time frame: at 10 years

Factor VII abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of factor VII for each patient at inclusion

Time frame: at 10 years

Factor VIII abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of factor VIII for each patient at inclusion

Time frame: at 10 years

Factor IX abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of factor IX for each patient at inclusion

Time frame: at 10 years

Factor X abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of factor X for each patient at inclusion

Time frame: at 10 years

Factor XI abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of factor XI for each patient at inclusion

Time frame: at 10 years

Fibrinogen abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of fibrinogen for each patient at inclusion

Time frame: at 10 years

D-dimer abnormalities in patients with chronic liver disease at different stages and controls without liver disease

mesure of D-dimer for each patient at inclusion

Time frame: at 10 years

Protein C abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of protein C for each patient at inclusion

Time frame: at 10 years

protein S abnormalities in patients with chronic liver disease at different stages and controls without liver disease

mesure of protein S for each patient at inclusion

Time frame: at 10 years

Willebrand factor abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of plasma Willebrand factor for each patient at inclusion

Time frame: at 10 years

Thrombin generation test abnormalities in patients with chronic liver disease at different stages and controls without liver disease

Mesure of thrombin generation test for each patient at inclusion

Time frame: at 10 years

Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts